

NOTICE: This is a translation of a notice in Japanese issued on June 24, 2016 and is made solely for the convenience of foreign shareholders. In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail.

Securities code: 4536

June 24, 2016

**RESOLUTION NOTICE OF
THE 104TH ANNUAL GENERAL MEETING OF SHAREHOLDERS OF
SANTEN PHARMACEUTICAL CO., LTD.**

Dear Shareholder:

We hereby inform you of the reports and the resolutions that were made, as set forth below, in the 104th Annual General Meeting of Shareholders of the Company that was held today.

Reports:

1. Reports on the Business Report, Consolidated Financial Statements and Financial Statements for the 104th Business Term (April 1, 2015 to March 31, 2016)
2. Reports on the Audit Reports by the Accounting Auditors and the Board of Corporate Auditors on the Consolidated Financial Statements for the 104th Business Term (April 1, 2015 to March 31, 2016)

As regards the items set forth above, the contents thereof were reported.

Resolved Items:

Proposal No. 1: Appropriation of Surplus

As regards this item, the term-end dividends of profits were resolved to be JPY 13 per share as per the original proposal. Consequently, the total dividends for the annual business term, including the interim dividends previously distributed are JPY 25 per share.

Proposal No. 2: Appointment of Five (5) Directors

As regards this item, Akira Kurokawa, Sadatoshi Furukado, Akihiro Okumura, Takayuki Katayama and Kanoko Oishi were appointed as per the original proposal; each of them assumed their respective offices.

Akihiro Okumura, Takayuki Katayama and Kanoko Oishi are Outside Directors.

Proposal No. 3: Appointment of One (1) Corporate Auditor

As regards this item, Masashi Murata was appointed as per the original proposal and assumed his office.

Yours very truly,

Akira Kurokawa
Representative Director
President & CEO
SANTEN PHARMACEUTICAL CO., LTD.
9-19, Shimoshinjo 3-chome, Higashiyodogawa-ku, Osaka, Japan
[Corporate Headquarters: 4-20, Ofuka-cho, Kita-ku, Osaka, Japan]

ANNOUNCEMENT

At the Board of Directors meeting, which was held after the close of this Annual General Meeting of Shareholders, Akira Kurokawa was appointed as President and CEO. He assumed the said offices.

As a result thereof, the Directors and Corporate Auditors of the Company and Corporate Officers of the Company shall be as follows:

Directors and Corporate Auditors

Akira Kurokawa	President and CEO
Sadatoshi Furukado	Director Vice President, Executive Corporate Officer Human Resources Development and Corporate Administration
Akihiro Okumura *	Director
Takayuki Katayama *	Director
Kanoko Oishi *	Director
Masashi Murata	Standing Corporate Auditor
Yutaka Mizuno**	Corporate Auditor
Koichi Matsuzawa **	Corporate Auditor
Seiichiro Adachi **	Corporate Auditor

* The Outside Directors (indicated by an asterisk (*) next to their names) are Independent Officers (as set forth in Article 436-2, Paragraph 1 of the Securities Listing Regulations of the Tokyo Stock Exchange, Inc.; hereinafter, the same classification shall apply.)

The Outside Corporate Auditors (indicated by two asterisks ()) next to their names) are Independent Officers.

Corporate Officers (excluding Corporate Officers who are also Members of the Board)

Takeshi Ito	Executive Corporate Officer Japan Business Head of Japan Sales & Marketing, Prescription Pharmaceuticals
Akihiro Tsujimura	Executive Corporate Officer Head of Corporate Development Division Asia and North America Businesses President & CEO of Santen Inc.
Masamichi Sato	Senior Corporate Officer Head of CSR & General Affairs Division CEO of Santen Business Services Co., Ltd.
Naveed Shams	Senior Corporate Officer Chief Scientific Officer (CSO) Head of Global Research & Development
Atsutoshi Ota	Senior Corporate Officer Head of Human Resources Development Division
Kazuo Koshiji	Senior Corporate Officer Chief Financial Officer (CFO) Head of Finance Division
Shigeo Taniuchi	Senior Corporate Officer Head of Santen Europe President of Santen Holdings EU B.V.
Kenji Morishima	Corporate Officer Head of Pharmaceutical Technology Development
Akio Kimura	Corporate Officer Head of Global Product Supply Head of Global Quality Compliance
Noriaki Yamamoto	Corporate Officer Chief Information Officer (CIO) Head of Information Systems Division
Hiroyuki Yamazaki	Corporate Officer Head of Japan Prescription Pharmaceuticals Sales
Satoshi Suzuki	Corporate Officer Head of Asia Division
Ye Liu	Corporate Officer General Manager Santen Pharmaceutical (China) Co., Ltd.

End.